Latest

Beyond Boundaries: The Staying Power of Emerging Markets

Emerging country market-access experts from McKinsey & Co. sit down with Pharm Exec to discuss next-level strategies needed to build sustainable local businesses that maximize patient access to the product portfolio.

Industry and Patients: An Evolving Partnership

Pharm Exec talks to Jane Griffiths, Company Group Chairman, Janssen EMEA, about how the relationship between industry and patients is maturing.

New & Noteworthy

Pharma dot-gov: A New Business Model

An advocate of supply chain business system automation offers a six-pronged approach to adapting to a new age of mounting regulation and customer expectations.

Canada's Rx&D: Fresh Start for a New Era

Canada’s Rx&D recently changed its name—with a mission of bridging the many points of collaboration that drive the process of modern drugs, from discovery to market. William Looney reports.

The Digital Marketing Platforms That Will Stick Around

Peter Houston looks at the social and digital channels that look likely to still be here by the end of the year.

Branding: When One is Not Enough

Ram Subramanian and Dr. Rehan Baqri discuss the power of a second brand in the evolving global healthcare market.

Sales & Marketing

The Digital Marketing Platforms That Will Stick Around

Peter Houston looks at the social and digital channels that look likely to still be here by the end of the year.

Branding: When One is Not Enough

Ram Subramanian and Dr. Rehan Baqri discuss the power of a second brand in the evolving global healthcare market.

Commercial Models for a New Healthcare Ecosystem

Companies must design local commercial models that enable them to deliver value stories tailored to the specific needs of organized customers and the characteristics of local ecosystems, writes Paul Darling.

SPONSORED CONTENT: Behind AmerisourceBergen's ThinkLive Event

Pharm Exec interviews AmerisourceBergen senior executive team members at the company’s annual ThinkLive customer relations event.

Featured eBooks

 

The Changing Contours of Drug Commercialization

"The Changing Contours of Drug Commercialization," a new e-book from the editors of Pharmaceutical Executive, sheds light on solutions and strategies uniquely within a manufacturer's own sphere of control that can help navigate the often unforgiving transition from registration to the real-world battle for clinical acceptance and market share. 

 

Patient-Centric Approach to Product Commercialization

The industry's much talked-about patient-centered approach requires more than lip-service and organizational redesigns. In order for the patient to emerge center stage in a commercial approach, it's necessary for manufacturers to shift prioritization's to help the greatest number of patients gain access and remain on treatments.

 

The Path To Market Access: Winning Strategies To Build Value With Payers

Success in today’s rapidly changing market access world depends on understanding your product’s value through the eyes of payers and shaping crucial value communication around the needs of market access stakeholders as much as it does on developing solid evidence of the value of your product.

 

 

View all eBooks

PEspeaks

Morgan Moments: A Closer Reading of the JP Morgan Investor Conference

William Looney identifies three areas where the insular, often maladroit tone of the industry-investor dialogue may be morphing to something more grounded in the larger societal context of healthcare.

Pharma Smackdown on Capitol Hill

Valeant and Turing's fuzzy explanations of pricing practices to the House Oversight and Government Reform Committee cast a shadow over the broader industry, writes Jill Wechsler.

Presidential Candidates & Rx Policy

As the nation heads towards its first presidential primaries of the 2016 election, pharmaceutical executives should take a few minutes to consider where the leading candidates stand on U.S. Rx policy.

Pharma 2016: Hot Topics, Burning Questions

Pharm Exec Editorial Advisory Board member Cliff Kalb poses some of the pertinent questions he expects the pharma industry will be asking this year.

From the Editor

Morgan Moments: A Closer Reading of the JP Morgan Investor Conference

William Looney identifies three areas where the insular, often maladroit tone of the industry-investor dialogue may be morphing to something more grounded in the larger societal context of healthcare.

2016: A Biopharma Market in Flux

Pharm Exec Editor-in-Chief William Looney offers his take on the opportunities, threats, and other big issues facing the industry in the new year.

Strategy

Pharma dot-gov: A New Business Model

An advocate of supply chain business system automation offers a six-pronged approach to adapting to a new age of mounting regulation and customer expectations.

Commercial Models for a New Healthcare Ecosystem

Companies must design local commercial models that enable them to deliver value stories tailored to the specific needs of organized customers and the characteristics of local ecosystems, writes Paul Darling.

CEO Snapshot: Subhanu Saxena, Cipla

Julian Upton sits down with Subhanu Saxena for an update on Cipla's plans to leverage its historic visibility as an emerging market champion to the next level of global leadership in biopharma.

Regulatory

Pharma Smackdown on Capitol Hill

Valeant and Turing's fuzzy explanations of pricing practices to the House Oversight and Government Reform Committee cast a shadow over the broader industry, writes Jill Wechsler.

Congress to Keep a Close Watch on FDA

GOP critics of the Agency are planning more oversight of regulatory programs and policies. Jill Wechsler reports.

Rough Road Ahead for Innovation

The last few months have been tough for pharmaceutical companies, and the political environment in Washington isn’t likely to improve in the coming year, writes Jill Wechsler.

Europe

What the Drug Industry Stands to Gain (or Lose) from a "Brexit"

It's an obvious question for every pharmaceutical executive — and the question no-one dares to answer: what happens if the UK leaves the EU?

R&D

Harvard Business School Launches Precision Trials Challenge

Harvard Business School has launched a competition to generate ideas to bring precision diagnostics and therapies to market more quickly by reinventing the clinical trials process.

Pressure Mounts for Greater Clinical Trial Data Transparency

Large pharma companies have fallen “below legal and ethical standards” for making public information from the relevant clinical trials, according to a report from Bioethics International.

lorem ipsum